US 11,338,003
Application 16/605,066 · Granted May 24, 2022
Methods of treating bladder cancer with an oncolytic virus
Estimated expiration
February 1, 2039
12y 75d remaining
Earliest effective filing
Apr 13, 2018
+ 20 years
Apr 13, 2038
PTA +294d
Feb 1, 2039
No TD
—
Final
Feb 1, 2039
- Earliest effective filing
- Apr 13, 2018
- + 20 years
- Apr 13, 2038
- PTA +294d
- Feb 1, 2039
- No TD
- —
- Final
- Feb 1, 2039
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- October 14, 2019
- Earliest effective filing
- April 13, 2018
- Issue date
- May 24, 2022
- PTA
- +294 days
- Base expiry (before PTA)
- April 13, 2038
April 13, 2018 + 20 years = April 13, 2038 + 294 PTA days = February 1, 2039
- National stage entry of application PCTUS2018027549, filed Apr 13, 2018
- PRO62/485,805 — Provisional — not used for base term
- PRO62/500,729 — Provisional — not used for base term
- PRO62/500,729 — Provisional — not used for base term
- PRO62/485,805 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
You have the date. Your AI can have the file.
Application 16/605,066 · US 11,338,003
PatentReply compiles the prosecution history behind US 11,338,003: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new published application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US11338003Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.